Compare Hasbro, Inc. (HAS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Hasbro, Inc. trades at $96.94 (market cap $13.46B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Hasbro, Inc. is the larger of the two by market cap, and Hasbro, Inc. pays a 2.93% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HAS | SYRE | |
|---|---|---|
Market Cap | $13.46B | $7.35B |
Volume | 1,300,226 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $108.92 |
52-Week Low | $74.13 | $22.18 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $15.65B | $6.35B |
Dividend Yield | 2.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $95.94, up 1.28% on the day, with strong technical momentum as the stock approaches resistance near $96. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results due October 20. Revenue grew to $4.7B in 2025, though net income was negative due to one-time charges, while 2026 projections show a return to profitability with $794M net income expected. Analyst consensus is bullish with a $107.60 price target and no sell ratings among 33 analysts.
Outlook remains positive given earnings momentum and gaming segment strength, particularly Magic: The Gathering's 27% growth. Risks include high debt levels (59.09% debt-to-asset ratio) and sensitivity to consumer discretionary spending. The stock offers 12% upside to consensus target with institutional buying support from firms like HSBC and Virginia Retirement Systems.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
